$PLX
Protalix BioTherapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021007157 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $11.32M $21.65M
YoY Change -47.7% 107.34%
Cost Of Revenue $4.765M $3.426M
YoY Change 39.08% 67.53%
Gross Profit $6.555M $18.22M
YoY Change -64.02% 117.16%
Gross Profit Margin 57.91% 84.17%
Selling, General & Admin $3.138M $3.187M
YoY Change -1.54% 42.91%
% of Gross Profit 47.87% 17.49%
Research & Development $7.122M $10.34M
YoY Change -31.12% -11.63%
% of Gross Profit 108.65% 56.75%
Depreciation & Amortization $286.0K $376.0K
YoY Change -23.94% -7.16%
% of Gross Profit 4.36% 2.06%
Operating Expenses $10.26M $13.53M
YoY Change -24.15% -2.9%
Operating Profit -$3.705M $4.693M
YoY Change -178.95% -184.8%
Interest Expense -$1.820M -$3.030M
YoY Change -39.93% 75.14%
% of Operating Profit -64.56%
Other Income/Expense, Net -$1.821M -$3.026M
YoY Change -39.82% 74.91%
Pretax Income -$5.480M $1.670M
YoY Change -428.14% -123.0%
Income Tax
% Of Pretax Income
Net Earnings -$5.475M $1.667M
YoY Change -428.43% -122.95%
Net Earnings / Revenue -48.37% 7.7%
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$0.14 $0.10
COMMON SHARES
Basic Shares Outstanding 39.93M
Diluted Shares Outstanding 39.93M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.80M $14.20M
YoY Change 39.44% -53.29%
Cash & Equivalents $19.83M $14.17M
Short-Term Investments
Other Short-Term Assets $1.754M $25.20M
YoY Change -93.04% 1377.14%
Inventory $13.92M $9.500M
Prepaid Expenses
Receivables $4.599M $8.900M
Other Receivables $0.00 $0.00
Total Short-Term Assets $90.70M $57.80M
YoY Change 56.92% 22.09%
LONG-TERM ASSETS
Property, Plant & Equipment $4.828M $10.70M
YoY Change -54.88% 76.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $14.40M
YoY Change -87.5% 700.0%
Total Long-Term Assets $12.09M $25.10M
YoY Change -51.82% 83.17%
TOTAL ASSETS
Total Short-Term Assets $90.70M $57.80M
Total Long-Term Assets $12.09M $25.10M
Total Assets $102.8M $82.90M
YoY Change 24.0% 35.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.400M $9.400M
YoY Change -31.91% 59.32%
Accrued Expenses $1.400M $1.100M
YoY Change 27.27% -15.38%
Deferred Revenue $2.560M
YoY Change
Short-Term Debt $0.00 $4.300M
YoY Change -100.0%
Long-Term Debt Due $55.40M
YoY Change
Total Short-Term Liabilities $80.86M $47.60M
YoY Change 69.88% 76.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $52.00M
YoY Change -100.0% -3.7%
Other Long-Term Liabilities $26.00K $14.10M
YoY Change -99.82% 166.54%
Total Long-Term Liabilities $7.427M $66.10M
YoY Change -88.76% -29.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $80.86M $47.60M
Total Long-Term Liabilities $7.427M $66.10M
Total Liabilities $88.29M $113.8M
YoY Change -22.42% -5.87%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.50M -$30.88M
YoY Change
Total Liabilities & Shareholders Equity $102.8M $82.90M
YoY Change 24.0% 35.8%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$5.475M $1.667M
YoY Change -428.43% -122.95%
Depreciation, Depletion And Amortization $286.0K $376.0K
YoY Change -23.94% -7.16%
Cash From Operating Activities -$9.834M -$7.117M
YoY Change 38.18% -2.19%
INVESTING ACTIVITIES
Capital Expenditures $386.0K $66.00K
YoY Change 484.85% -61.18%
Acquisitions
YoY Change
Other Investing Activities $28.00K $35.00K
YoY Change -20.0% -369.23%
Cash From Investing Activities -$30.68M -$35.08M
YoY Change -12.53% 9355.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.575M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.11M 38.61M
YoY Change 9.08%
NET CHANGE
Cash From Operating Activities -9.834M -7.117M
Cash From Investing Activities -30.68M -35.08M
Cash From Financing Activities 42.11M 38.61M
Net Change In Cash 1.565M -3.626M
YoY Change -143.16% -52.58%
FREE CASH FLOW
Cash From Operating Activities -$9.834M -$7.117M
Capital Expenditures $386.0K $66.00K
Free Cash Flow -$10.22M -$7.183M
YoY Change 42.28% -3.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-33357
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
CY2021Q1 dei City Area Code
CityAreaCode
(201)
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
696-9345
CY2021Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2021Q1 dei Trading Symbol
TradingSymbol
PLX
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45382831
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
26000
CY2021Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
55372000
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
54427000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4086000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
80861000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86474000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
858000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1716000
CY2021Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2224000
CY2020Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2263000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4319000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4467000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19830000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18265000
CY2021Q1 plx Short Term Bank Deposits
ShortTermBankDeposits
50600000
CY2020Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
20280000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4599000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1754000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2096000
CY2021Q1 us-gaap Inventory Net
InventoryNet
13915000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
90698000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55723000
CY2021Q1 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1776000
CY2020Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1799000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4828000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4845000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5490000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5567000
CY2021Q1 us-gaap Assets
Assets
102792000
CY2020Q4 us-gaap Assets
Assets
67934000
CY2021Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6376000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7221000
CY2021Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
15167000
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
13926000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1386000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1420000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2560000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5394000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7427000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8497000
CY2021Q1 us-gaap Liabilities
Liabilities
88288000
CY2020Q4 us-gaap Liabilities
Liabilities
94971000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14504000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102792000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67934000
CY2021Q1 us-gaap Revenues
Revenues
11320000
CY2020Q1 us-gaap Revenues
Revenues
21646000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
4765000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
3426000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7122000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10340000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3138000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3187000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3705000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4693000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2156000
CY2020Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3229000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
335000
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
203000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1821000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3026000
CY2021Q1 us-gaap Other Income
OtherIncome
51000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1667000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.10
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39933972
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17381074
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
CY2020Q1 plx Issuance Of Common Stock And Warrants Net Of Issuance Cost Value
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
41343000
CY2020Q1 plx Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants
AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
4000000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
431000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1667000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-30881000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
CY2021Q1 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000
CY2021Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
306000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14504000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5475000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1667000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
816000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
431000
CY2021Q1 us-gaap Depreciation
Depreciation
286000
CY2020Q1 us-gaap Depreciation
Depreciation
376000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
168000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
241000
CY2021Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
42000
CY2020Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
44000
CY2021Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
14000
CY2020Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-59000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-37000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1565000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3626000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18265000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17792000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19830000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
945000
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
820000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3692000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7171000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2282000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4091000
CY2021Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-42000
CY2020Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-10000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
833000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1333000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
575000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2611000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-25000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-299000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9834000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7117000
CY2021Q1 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
CY2020Q1 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
35000000
CY2021Q1 plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
7500000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
386000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
CY2021Q1 plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-12000
CY2020Q1 plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-22000
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
28000
CY2020Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
35000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30684000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35079000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
CY2021Q1 plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37625000
CY2020Q1 plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
38607000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42114000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38607000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-31000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14166000
CY2021Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
202000
CY2020Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
147000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
122000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
233000
CY2020Q1 plx Note Receivable From Issuance Of Common Stock And Warrants Net Of Issuance Cost
NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
2736000
CY2021Q1 plx Interest Received Net
InterestReceivedNet
136000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8749999
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40200000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.60
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10694517
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26769693
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3427000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3347000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2273000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2887000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8215000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6848000
CY2021Q1 us-gaap Inventory Net
InventoryNet
13915000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000

Files In Submission

Name View Source Status
0001558370-21-007157-index-headers.html Edgar Link pending
0001558370-21-007157-index.html Edgar Link pending
0001558370-21-007157.txt Edgar Link pending
0001558370-21-007157-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20210331.xsd Edgar Link pending
plx-20210331x10q.htm Edgar Link pending
plx-20210331x10q005.jpg Edgar Link pending
plx-20210331x10q006.jpg Edgar Link pending
plx-20210331x10q007.jpg Edgar Link pending
plx-20210331x10q_htm.xml Edgar Link completed
plx-20210331xex10d1.htm Edgar Link pending
plx-20210331xex10d2.htm Edgar Link pending
plx-20210331xex10d3.htm Edgar Link pending
plx-20210331xex31d1.htm Edgar Link pending
plx-20210331xex31d2.htm Edgar Link pending
plx-20210331xex32d1.htm Edgar Link pending
plx-20210331xex32d2.htm Edgar Link pending
plx-20210331_cal.xml Edgar Link unprocessable
plx-20210331_def.xml Edgar Link unprocessable
plx-20210331_lab.xml Edgar Link unprocessable
plx-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending